15. Supplemental Disclosures Other Current Assets Other current assets consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
Settlement payment due from Sarepta |
|
$ |
39,000 |
|
|
$ |
— |
|
Net cost reimbursement due from AbbVie |
|
|
7,493 |
|
|
|
10,871 |
|
Accrued interest on investments |
|
|
961 |
|
|
|
1,004 |
|
Other |
|
|
692 |
|
|
|
1,030 |
|
|
|
$ |
48,146 |
|
|
$ |
12,905 |
|
Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
Accrued personnel costs |
|
$ |
16,037 |
|
|
$ |
17,418 |
|
Accrued external research and development expenses |
|
|
8,412 |
|
|
|
10,229 |
|
Accrued external general and administrative expenses |
|
|
1,880 |
|
|
|
1,301 |
|
Accrued royalties and sublicense fees |
|
|
1,150 |
|
|
|
8,652 |
|
Accrued purchases of property and equipment |
|
|
242 |
|
|
|
33 |
|
Other |
|
|
1,890 |
|
|
|
757 |
|
|
|
$ |
29,611 |
|
|
$ |
38,390 |
|
|